Skip to main content

Advertisement

SpringerLink
Log in

Targeted cancer therapies

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Market for targeted cancer therapies.

References

  1. IMS Health. Press release (1 April). IMS Health reports U.S. prescription sales grew 5.1 percent in 2009, to $300.3 billion. IMS Health website [online], (2010).

  2. Kerbel, R. S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171–1175 (2006).

    Article  CAS  Google Scholar 

  3. Sawyers, C. L. Cancer: mixing cocktails. Nature 449, 993–996 (2007).

    Article  CAS  Google Scholar 

  4. Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563–572 (2009).

    Article  CAS  Google Scholar 

  5. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

    Article  Google Scholar 

  6. Storey, S. Chronic myelogenous leukaemia market. Nature Rev. Drug Discov. 8, 447–448 (2009).

    Article  CAS  Google Scholar 

  7. Bach, P. B. Limits on Medicare's ability to control rising spending on cancer drugs. N. Engl. J. Med. 360, 626–633 (2009).

    Article  CAS  Google Scholar 

  8. WHO. Cancer. WHO website [online], (2010).

  9. Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saurabh Aggarwal is a Principal at PAREXEL Consulting, Suite 350, 4600 East West Highway, Bethesda, Maryland 20814, USA. saurabh.aggarwal@parexel.com; saurabhaggarwal@gmail.com,

    Saurabh Aggarwal

Authors
  1. Saurabh Aggarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Supplementary information

Supplementary information S1 (table)

Approved targeted cancer therapies (PDF 69 kb)

Supplementary information S2 (table)

Expansion of indications for imatinib: US FDA approvals (PDF 61 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aggarwal, S. Targeted cancer therapies. Nat Rev Drug Discov 9, 427–428 (2010). https://doi.org/10.1038/nrd3186

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3186

  • Springer Nature Limited

This article is cited by

Search

Navigation